Evommune, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Evommune reported Q2 2026 results with cash of $288.0M (vs. $216.7M at year-end 2025), runway through 2028. EVO756 atopic dermatitis Phase 2b (N=120) top-line expected September 2026; migraine prophylaxis Phase 2b (N=330) initiated July 2026 with 2027 data. EVO756 CSU program discontinued following failed Phase 2b (missed primary endpoint). EVO301 positive Phase 2a AD data to be presented; Phase 2b planned mid-2027. Net loss widened to $53.9M for six months (vs. $28.1M prior year); R&D expenses $43.7M (vs. $34.0M).
Why this rating
Multiple near-term catalysts (data in 2-3 months, migraine expansion) offset CSU failure and accelerating burn. Cash sufficient for pipeline; relative to $322.5M assets, $288M cash is strong but net losses doubling signals runway pressure. Moderate materiality.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.